These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 14506170

  • 1. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
    She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3773-8. PubMed ID: 14506170
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG.
    Clin Cancer Res; 2000 Dec 01; 6(12):4885-92. PubMed ID: 11156248
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2002 Oct 01; 8(10):3250-8. PubMed ID: 12374696
    [Abstract] [Full Text] [Related]

  • 4. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM, She Y, Lee F, Chen J, Scher HI.
    Clin Cancer Res; 2002 Dec 01; 8(12):3870-6. PubMed ID: 12473602
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 6. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 7. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH.
    Clin Cancer Res; 2002 Nov 15; 8(11):3496-502. PubMed ID: 12429640
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2001 May 15; 7(5):1459-65. PubMed ID: 11350918
    [Abstract] [Full Text] [Related]

  • 9. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM, Li J, Armstrong EA, Harari PM.
    Cancer Res; 2002 Aug 01; 62(15):4300-6. PubMed ID: 12154033
    [Abstract] [Full Text] [Related]

  • 10. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
    Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH.
    Cancer Res; 2002 Oct 15; 62(20):5749-54. PubMed ID: 12384534
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).
    Burdak-Rothkamm S, Rübe CE, Nguyen TP, Ludwig D, Feldmann K, Wiegel T, Rübe C.
    Strahlenther Onkol; 2005 Mar 01; 181(3):197-204. PubMed ID: 15756525
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, Nakashiro K, Hamakawa H.
    Am J Clin Oncol; 2003 Oct 01; 26(5):e150-6. PubMed ID: 14528090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.